Radiopharmaceuticals are radioisotopes bound to biological molecules able to target specific organs, tissues or cells within the human body. These radioactive drugs can be used for the diagnosis and, increasingly, for the therapy of diseases.
The diagnostic radiopharmaceutical market is driving due to the factors such as increasing prevalence of chronic diseases and improvement of healthcare institutions with safety measures. In addition, development and launch of new products in the developing nations of the world are likely to offer growth opportunities for market players.
The "Diagnostic Radiopharmaceutical Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of diagnostic radiopharmaceutical market with detailed market segmentation by imaging modality and application. The diagnostic radiopharmaceutical market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in diagnostic radiopharmaceutical market and offers key trends and opportunities in the market.
The diagnostic radiopharmaceutical market is segmented on the basis of imaging modality and application. Based on imaging modality, the market is segmented as Tc-99, Tl-201, Ga-67, I-123, F-18, Rb-82, and others. On the basis of application, the market is segmented into cardiology, neurology, thyroid, and others.
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the diagnostic radiopharmaceutical market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The diagnostic radiopharmaceutical market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting diagnostic radiopharmaceutical market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors affecting the diagnostic radiopharmaceutical market in these regions.
Get more information on this report :
The report covers key developments in the diagnostic radiopharmaceutical market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from diagnostic radiopharmaceutical market are anticipated to have lucrative growth opportunities in the future with the rising demand for diagnostic radiopharmaceutical in the global market. Below mentioned is the list of few companies engaged in the diagnostic radiopharmaceutical market.
The report also includes the profiles of key players in diagnostic radiopharmaceutical market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered financial information of last 3 years, key development in past five years.
Cardinal Health, Inc.
Lanthus Holdings, Inc.
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.
Get more information on this report :
The List of Companies
1. Bayer AG
2. General Electric
3. Cardinal Health, Inc.
4. Nordion Inc.
5. Siemens Healthineers
6. Bracco Imaging
7. Guerbet Group
9. NTP Radioisotopes
10. Lanthus Holdings, Inc.